Lincoln Pharmaceuticals Share Price

NSE
584.4
-13.00 (2.20%)
LINCOLN • 13 Jun, 2025 | 03:29 PM
BUY

1Y Annualised Return

-3.74%

3Y Annualised Return

25.65%

5Y Annualised Return

29.76%

The current prices are delayed, login or Open Demat Account for live prices.

Lincoln Pharmaceuticals SIP Return Calculator

Over the past

1 year
3 years
5 years

Total Investment of ₹65,00,000

Would have become ₹63,79,483 (-1.85%)

Daily SIP of 25,000 would have become 63,79,483 in 1 year with a gain of -1,20,516 (-1.85%)

Lincoln Pharmaceuticals Stock Performance
Today’s Low - High
567.05
599.90
567.05
599.90
52 Week Low - High
499.00
979.50
499.00
979.50

Open

590.00

Prev. Close

597.40

Total Traded Value

5.95 Cr

View details of Market Depth
Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

1,173.64

Face Value

10

Turnover (in lacs)

595.07

Key Metrics
Qtr Change %
40.18% Fall from 52W High
11.2
Dividend yield 1yr %
Below industry Median
0.3

Lincoln Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Lincoln Pharmaceuticals Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
168.18 Cr
146.55 Cr
161.21 Cr
147.28 Cr
142.49 Cr

Lincoln Pharmaceuticals Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
645.71 Cr
614.97 Cr
532.78 Cr
482.12 Cr
429.85 Cr
397.53 Cr

Lincoln Pharmaceuticals Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
11.58 Cr
20.77 Cr
26.33 Cr
23.67 Cr
18.6 Cr

Lincoln Pharmaceuticals Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
82.35 Cr
93.3 Cr
72.9 Cr
69.36 Cr
62.25 Cr
51.47 Cr
Lincoln Pharmaceuticals Result Highlights
  • Lincoln Pharmaceuticals Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 28.5%.

  • Its expenses for the quarter were up by 0.4% QoQ and 28.1% YoY.

  • The net profit decreased 10.4% QoQ and increased 48.1% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 9.3 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals shareholding Pattern

Promoter
49.8%
Foreign Institutions
5%
Public
45.2%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45.1%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45%
Promoter
49.8%
Foreign Institutions
4%
Public
46.2%
Promoter
49.5%
Foreign Institutions
3.9%
Domestic Institutions
0.1%
Public
46.5%
Promoter
49.8%
Foreign Institutions
3.2%
Domestic Institutions
0.1%
Public
46.9%

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
584.4
Current Price
Bullish Moving Averages
10
Bearish Moving Averages
6
5Day EMA
584.50
10Day EMA
577.10
12Day EMA
575.50
20Day EMA
572.60
26Day EMA
572.00
50Day EMA
576.50
100Day EMA
601.20
200Day EMA
625.80
5Day SMA
586.00
10Day SMA
571.50
20Day SMA
569.20
30Day SMA
571.40
50Day SMA
570.00
100Day SMA
595.80
150Day SMA
654.30
200Day SMA
665.90
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
56090 Rs
107031 Rs
Week Rs
59016 Rs
109847 Rs
Month Rs
50646 Rs
97172 Rs
Resistance & Support
584.30
Pivot
Resistance
First Resistance
601.55
Second Resistance
617.15
Third Resistance
634.40
Support
First Support
568.70
Second support
551.45
Third Support
535.85
Relative Strength Index
56.49
Money Flow Index
71.62
MACD
3.55
MACD Signal
-0.68
Average True Range
20.10
Average Directional Index
19.39
Rate of Change (21)
-2.64
Rate of Change (125)
-37.83
Shareholding
Name
Holding Percent
Rimo Capital Fund Lp
1.33

Lincoln Pharmaceuticals Latest News

27 MAY 2025 | Tuesday

Lincoln Pharmaceuticals targets 1000 crore revenues in next 3 years

23 MAY 2025 | Friday

Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication

22 MAY 2025 | Thursday

Lincoln Pharma posts Rs 11.62 cr profit for Jan-Mar; revenue at Rs 161 cr

View More

Lincoln Pharmaceuticals Company background

Founded in: 1995
Managing director: Mahendra G Patel
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022.

As of 13 Jun, 2025, LINCOLN share price is ₹586. The stock opened at ₹590 and had closed at ₹597.4 the previous day. During today’s trading session, LINCOLN share price moved between ₹567.05 and ₹599.90, with an average price for the day of ₹583.00. Over the last 52 weeks, the stock has recorded a low of ₹499.00 and a high of ₹979.50. In terms of performance, LINCOLN share price has declined by 37% over the past six months and has declined by 3.74% over the last year.

Read More

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹584.4 in NSE and ₹584.1 in BSE as on 13/6/2025.

Lincoln Pharmaceuticals share price in the past 1-year return was -5.58. The Lincoln Pharmaceuticals share hit a 1-year low of Rs. 499 and a 1-year high of Rs. 979.5.

The market cap of Lincoln Pharmaceuticals is Rs. 1173.64 Cr. as of 13/6/2025.

The PE ratios of Lincoln Pharmaceuticals is 14.24 as of 13/6/2025.

The PB ratios of Lincoln Pharmaceuticals is 1.74 as of 13/6/2025

You can easily buy Lincoln Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -